As a new foreign trade service provider driven by both technology commercialization and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory goods of acetyl L-carnitine hydrochloride from multiple well-known brands. With over ten years of market experience as a tech-driven foreign trade service provider, HiSiaddi possesses rich practical experience in product compliance issues through technological cooperation with manufacturers. Below is a case of resolving compliance problems of acetyl L-carnitine hydrochloride handled by HiSiaddi.
Please contact HiSiaddi customer service if you need consultation on more compliance issues of acetyl L-carnitine hydrochloride products.
The purchasing party is BIOMEDISAN Biopharmaceutical Co., Ltd. based in Milan, Italy. With over 20 years of deep engagement in R&D and production of EU special medical foods, prescription-grade brain health preparations and postoperative medical nutrient solutions, its products cover public hospital pharmacies across Italy, high-end organic health product supermarket chains in Switzerland and special medical channels in six EU countries. Product access complies with EP, USP Pharmacopoeia, EU REACH registration, EFSA raw material safety assessment, dual KOSHER/HALAL religious certifications, TSE/BSE animal-free statements and full set of strict regulations for EU API GMP market access. Positioned as a mid-to-high-end European pharmaceutical raw material purchaser, it rejects low-cost low-grade food raw materials, with a stable annual purchase volume of 29 tons of acetyl L-carnitine hydrochloride split into 6 batches delivered monthly in separate lots, exclusively used for two terminal products: medical enteric tablets and high-concentration acidic oral nutrient solutions.
The client had long sourced pharmaceutical-grade acetyl L-carnitine hydrochloride imported from Switzerland before launching a Chinese-origin raw material replacement project in 2025 due to shrinking local EU API production capacity, successive year-on-year raw material price hikes and extended ocean delivery cycles exceeding 70 days. After independently contacting three major domestic raw material manufacturers to negotiate procurement and finalizing sample indicators, quotations and delivery cycles, five major compliance obstacles emerged successively approaching the shipment node of the first 5.5-ton bulk order: incomplete EU market access qualifications, gaps in REACH pre-registration, document systems inconsistent with Italian customs specifications, mismatched coverage categories of religious certifications and incomplete full-process traceability documents. The three manufacturers could only provide product test COA, lacking supporting service capabilities for full-set compliance documents required for EU special medical market access, unable to complete supplementary compliance formalities. If full compliance procedures could not be finalized and goods shipped within 45 days, the client would face raw material stockouts, production shutdown of three formulation production lines and suspension of semi-finished formulation R&D, with estimated direct economic losses exceeding 73,000 EUR. After fruitless inquiries from multiple parties, the client fully entrusted HiSiaddi to coordinate full-process compliance rectification, qualification supplementation, document standardization and pre-inspection customs clearance work covering all items.
Core mandatory compliance standards of the client: Raw materials used for EU prescription drugs and special medical foods must simultaneously satisfy three layers of regulations: domestic Chinese export drug administration compliance, EU import drug administration market access and Italian customs clearance. All documents shall be compatible with the client’s EU finished product registration filing materials.
EU regulations clearly stipulate that APIs sold to the EU must obtain Export EU API Certificates issued by provincial drug administrations in China since 2013 to verify alignment of manufacturers’ GMP systems with EU GMP standards. Italian drug administration and customs regard this document as the primary verification material for API market access. Only one of the three cooperating manufacturers held domestic pharmaceutical GMP certificates without applying for special export EU certificates, while the remaining two only possessed food production qualifications, unable to issue official pharmaceutical API market access documents. Raw materials could only be declared downgraded as ordinary food raw materials for customs clearance instead of pharmaceutical-grade products, inconsistent with the client’s prescription drug raw material filing specifications, preventing raw materials from being applied to prescription formulation production.
As a chemical API, acetyl L-carnitine hydrochloride is subject to REACH regulation control for EU exports. Shipments exceeding 1 ton require completion of EU pre-registration and appointment of an EU local Only Representative (OR). Import country customs verify registration numbers, tonnage filing information and safety data sheets (SDS). None of the three manufacturers independently completed REACH pre-registration; partial samples adopted outdated batch registration numbers inconsistent with molecular formula and production process information of the current shipment batch. SDS compiled per outdated domestic national standards failed to comply with EU GHS classification labeling rules, preventing data entry and filing in Italian customs systems and resulting in direct cargo detention upon arrival at port.
The client’s terminal products are simultaneously sold to high-end pharmacies in Jewish and Muslim concentrated regions, with mandatory regulatory requirements for valid dual KOSHER and HALAL certifications for raw materials. Certificates must clearly mark pharmaceutical-grade acetyl L-carnitine hydrochloride product name, specifications and production workshops. Certificates held by the three manufacturers only covered general food-grade raw materials, with pharmaceutical refining workshops excluded from certification audit scope. Mismatch between certificate categories and purchased product grades led to judgment of non-compliant raw materials during EU supermarket and drug administration audits, preventing compliant shelf sales of finished products.
EU special medical raw material regulations require full-process traceability records covering raw material feeding, enzymatic synthesis, refining crystallization and drying & packaging for each batch of raw materials, alongside 6-month accelerated stability test reports of raw materials and special microbial test data to support the client’s finished product registration filing with Italian drug administration. Domestic manufacturers could only issue single-batch finished product COA test slips without upstream raw material source certificates, process records and stability research data. Incomplete documents failed to support the client’s finished product filing.
HiSiaddi set up a special team consisting of API compliance specialists, EU regulation consultants, domestic drug administration agency specialists and international certification coordination specialists, relying on years of practical experience in API export compliance to balance domestic regulations and Italian import supervision requirements, implementing rectification in four stages and completing full-set compliance documents within 38 days:
1. Eliminate two manufacturers with only food-grade qualifications from the original three, re-screen two domestic mid-to-high-end manufacturers with pharmaceutical API GMP production qualifications and compliant production lines, prioritizing Zhejiang Xianju and Hubei Chuwei as core suppliers;
2. HiSiaddi coordinated with local provincial drug administrations of manufacturers to organize full-set application materials including factory GMP on-site inspection records, production licenses, process specifications and historical export records, applying for Export EU API Certificates on behalf of manufacturers. Assisting drug administrations with document verification and on-site data review, official EU export API qualification documents were successfully obtained within 18 working days, satisfying mandatory EU drug administration market access requirements.
1. HiSiaddi coordinated with EU local compliance institutions to appoint an EU compliant local Only Representative (OR) for the 5.5-ton shipment, supplement REACH pre-registration documents of acetyl L-carnitine hydrochloride, update registered tonnage filing information, complete batch information entry in EU ECHA system and generate valid registration numbers;
2. Recompile MSDS safety data sheets in accordance with the latest EU GHS specifications, revise hazard classification, storage & transportation conditions, ingredient labeling and first-aid instructions, replacing outdated domestic SDS to ensure consistent data across customs clearance documents, registration documents and product labels.
1. HiSiaddi coordinated with authoritative international KOSHER and HALAL certification bodies, arranging designated manufacturers to open pharmaceutical refining workshops for third-party factory audit reviews, adding pharmaceutical-grade acetyl L-carnitine hydrochloride categories to the coverage scope of original certificates and completing certificate modification filing;
2. Issue batch-specific certification statements marked with production batch numbers and specification details, matching certificate validity periods and audit scope with the current shipment batch, meeting market access requirements for multi-religious regions across the EU.
1. Coordinate manufacturers to organize full-process traceability ledgers covering raw material procurement contracts, upstream raw material origin certificates, enzyme source statements, full-process production batch records and intermediate test reports from raw material incoming inspection to finished product delivery;
2. Coordinate laboratories to supplement accelerated stability tests of raw materials and special microbial limit testing, issuing stability research reports and full-item microbial test data complying with EP Pharmacopoeia specifications. All documents are compiled in bilingual Chinese and English, bound into complete files to satisfy both domestic export customs inspection and direct application for the client’s finished product registration filing with Italian drug administration.
Redesign outer carton bilingual labels in accordance with EU import packaging labeling regulations, marking product name, pharmacopoeia grade, production batch number, expiry date, REACH registration number, country of origin and storage conditions to avoid customs inspection and cargo detention risks caused by non-compliant labels. Adopt food & pharmaceutical-grade moisture-proof vacuum packaging, retain full temperature control records during container loading and supplement cold chain storage & transportation compliance documents.
After full review of all compliance documents, the first batch of 5.5 tons of pharmaceutical-grade acetyl L-carnitine hydrochloride completed normal customs clearance and was shipped from Shanghai Port to Genoa Port, Italy. HiSiaddi submitted full-set qualification documents to Italian import customs for pre-inspection in advance, enabling one-time smooth customs clearance upon cargo arrival without inspection detention or compliance objections. Raw materials passed full-item physicochemical and microbial incoming inspection complying with EP Pharmacopoeia standards and were put into tablet and nutrient solution production lines for smooth mass production, completely resolving the client’s production shutdown crisis.
The remaining annual order of 23.5 tons was shipped in 5 subsequent batches. HiSiaddi established a pre-inspection compliance review mechanism for each batch, verifying validity of qualifications, documents and certifications before delivery of every batch to ensure seamless matching of batch documents with EU regulations. Compared with original Swiss imported raw materials, the client’s overall procurement cost decreased by 22.8%, and ocean delivery cycle was shortened from 72 days to 34 days.
1. BIOMEDISAN of Italy completely terminated import channels from Swiss manufacturers, with full annual acetyl L-carnitine hydrochloride procurement locked to two domestic mid-to-high-end brands coordinated by HiSiaddi. In the following year, customized demand for ultra-low impurity raw materials specially for infant special medical drops was added, with an additional annual procurement order of 12 tons;
2. The client fully entrusted HiSiaddi with overall coordination of China procurement compliance work for various special medical APIs such as L-carnitine tartrate and GABA. Relying on the compliance implementation results of this project, HiSiaddi assisted cooperating manufacturers to optimize standardized EU compliance systems, successfully developing two equivalent mid-to-high-end European special medical pharmaceutical clients in France and Portugal.
Most domestic manufacturers of acetyl L-carnitine hydrochloride focus on product production and quotation, lacking research on segmented market regulations in the EU and other European and American countries. They can only provide product test reports without familiarity with compound compliance requirements including REACH, EU API market access, international religious certification and importing country drug administration filing. Restricted by strict domestic drug administration regulations, European mid-to-high-end special medical and prescription pharmaceutical enterprises impose meticulous and cumbersome requirements on full-chain raw material compliance documents, easily falling into compliance predicaments of qualification gaps and mismatched documents when purchasing Chinese raw materials.
Breaking the traditional foreign trade model of only raw material matching, HiSiaddi positions itself as a cross-border compliance third-party service provider, connecting full-chain compliance services covering domestic drug administration certification agency, EU regulation registration, international certification agency, standardized document compilation and pre-inspection customs clearance. It not only helps overseas mid-to-high-end clients resolve cross-border procurement compliance barriers and avoid economic losses from cargo detention and production shutdown, but also assists high-quality domestic API manufacturers to supplement international compliance weaknesses, escape low-end price competition and smoothly access high-value EU special medical and prescription API supply chains, achieving long-term win-win results for both supply and demand sides.
Please contact HiSiaddi customer service if you need consultation on more compliance issues of acetyl L-carnitine hydrochloride products.
+86-13120989737 
info@hisiaddi.com 
English
